Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AMSTERDAM, The Netherlands, Dec. 5, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present at the Oppenheimer 25th...
-
Amsterdam, The Netherlands, Dec. 1, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the third quarter of 2014. Corporate Highlights...
-
Amsterdam, The Netherlands, Nov. 21, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that it will be hosting an Investor Day and simultaneous...
-
AMSTERDAM, The Netherlands, Nov. 10, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Jörn Aldag, CEO, will present a corporate overview...
-
--Top-line Results Confirming Safety, Liver Transfection Presented at ESGCT Conference-- THE HAGUE, the Netherlands, Oct. 27, 2014 (GLOBE NEWSWIRE) -- The AIPGENE Consortium, a pan-European...
-
Amsterdam, The Netherlands, Sept. 25, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present at the Leerink Partners Rare...
-
AMSTERDAM, the Netherlands, Sept. 2, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the second quarter of 2014 and an update on...
-
AMSTERDAM, Netherlands, Aug. 11, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage...
-
AMSTERDAM, the Netherlands, and PARMA, Italy, Aug. 4, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading...
-
AMSTERDAM, the Netherlands, July 1, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the closing of an additional $10 million venture debt loan...